| セッション情報 | JDDW International Debate Session（Featured Lecture）5(JDDW)JDDW International Debate Session 「How to use irradiation in potentially curable gastric cancer? 」 |
|---|---|
| タイトル | IS1-5-2：Chemoradiation for Gastric Cancer: When and Where? |
| 演者 | T. S. Hong（Massachusetts General Hospital/Harvard Medical School, Gastrointestinal Radiation Oncology） |
| 共同演者 | |
| 抄録 | The standard of care for resectable gastric or gastro-esophageal (GE) junction cancer for patients who can tolerate a surgical procedure is surgical resection, but surgery alone is not optimal treatment for patients at high-risk for relapse. For patients with lower risk lesions (confined to gastric wall, nodes negative; T1-2N0M0), local-regional relapse risks are low, and adjuvant irradiation (RT) is usually not recommended except in select instances. Since both local-regional and systemic relapses are common after resection of high-risk gastric or GE junction cancers (beyond wall, nodes positive, or both; T3-4N0, TanyN+), adjuvant treatment is indicated for these patients. The results of Phase II/III trials that demonstrate a survival benefit for adjuvant pre-op RT or postop chemoRT vs surgery alone will be presented and compared with the results of adjuvant peri-op chemotherapy. The POET trial for pts with GE junction ACA found an advantage for preop chemoRT vs preop chemo alone (3-yr OS, 47.4 vs 27.7% , p=0.07; 3-yr local relapse free SR, 76.5 vs 59%, p=0.06). Pertinant adjuvant gastric cancer trials will be discussed. |
| 索引用語 |